fiercepharmaJanuary 10, 2019
Tag: crossed fingers , Review , FDA , crossed fingers
The J.P. Morgan Healthcare Conference opened Tuesday with some anticipation for GlaxoSmithKline CEO Emma Walmsley's talk, what with the pharma giant's recent deal to buy cancer drugmaker Tesaro. And ahead of Amgen CEO Bob Bradway's morning presentation, the company rolled out another round of price cuts on its cholesterol drug Repatha, which Bradway talked up along with its new migraine drug Aimovig.
But pricing hasn't been much on the agenda, except at Alexion, which says it needs an entirely new strategy. What has? Drug launches—Lilly's Aimovig rival Emgality, for one—and hoped-for FDA nods; diabetes rivalries and deal integrations; FDA tea leaves and, yes, one unexpected tax bill.
We're chronicling the daily events with continuously updated roundups, from news stories to executive remarks to excerpts from our own sideline interviews. If you missed our Monday rundown, with its latest additions a few hours before Tuesday's schedule began, find it here. And for all our FiercePharma coverage over the course of the conference, keep tabs on this page, and look here for FierceBiotech's own news.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: